The evolution of the matrix metalloproteinase inhibitor drug discovery program at Abbott Laboratories

Current Topics in Medicinal Chemistry

Volumn 4, Issue 12, 2004, Pages 1255-1267

  Wada, Carol K ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Biaryl hydroxamate; MMP inhibitor; MMPs; N formylhydroxylamine; Retrohydroxamate; SAR by NMR

Indexed keywords

ABT 518; ABT 770; BATIMASTAT; BENZOPHENONE; COLLAGENASE 3; GELATINASE A; GELATINASE B; HYDANTOIN DERIVATIVE; HYDROXAMIC ACID DERIVATIVE; INDOLE DERIVATIVE; INTERSTITIAL COLLAGENASE; KETONE DERIVATIVE; MACROCYCLIC COMPOUND; MATRILYSIN; MATRIX METALLOPROTEINASE INHIBITOR; METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; PYRROLE DERIVATIVE; STROMELYSIN; STROMELYSIN INHIBITOR; SUCCINIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CANCER MODEL; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG CLEARANCE; DRUG DESIGN; DRUG HALF LIFE; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; REVIEW; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TOXICITY TESTING;

ANIMALS; DRUG DESIGN; DRUG INDUSTRY; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MATRIX METALLOPROTEINASES; PROTEASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 4444341426     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026043388015     Document Type: Review

References (24)

1. Doherty, T. M.; Asotra, K.; Pei, D.; Uzui, H.; Wilkin, D. J.; Shah, P. K.; Rajavashisth, T. B. Therapeutic Developments in Matrix Metalloproteinase Inhibition. Expert Opin. Ther. Patents 2001, 12, 665-707.
2. Foda, H. D.; Zucker, S. Matrix Metalloproteinases in Cancer Invasion, Metastasis and Angiogenesis. Drug Discovery Today 2001, 6(9), 478-482.
3. Hidalgo, M.; Eckhardt, S.G. Development of Matrix Metalloproteinase Inhibitors in Cancer Therapy. J. Natl. Cancer Inst. 2001, 93(7), 178-193.
4. Michaelides, M. R.; Curtin, M. L. Recent Advances in Matrix Metalloproteinase Inhibitors Research. Curr. Pharm. Des. 1999, 5(10), 787-819.
5. Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. H. Design and Therapeutic Application of Matrix Metalloproteinase Inhibitors. Chem. Rev. 1999, 99(9), 2735-2776.
6. Grams, F.; Crimmin, M.; Hinnes, L.; Huxley, P.; Pieper, M.; Teschesche, H.; Bode, W. Structure Determination and Analysis of Human Neutrophil Collagenase Complexed With a Hydroxamate Inhibitor. Biochemistry 1995, 34, 1401214020.
7. Steinman, D. H.; Curtin, M. L.; Garland, R. B.; Davidsen, S. K.; Heyman, H. R.; Holms, J. H.; Albert, D. H.; Magoc, T. J.; Nagy, I. B.; Marcotte, P. A.; Li, J.; Morgan, D. W.; Hutchins, C.; Summers, J. B. The Design, Synthesis, and Structure-Activity Relationships of a Series of Macrocyclic MMP Inhibitors. Bioorg. Med. Chem. Lett. 1998, 8, 2087-2092.
8. Molecular Simulations, Inc., San Diego, California.
9. Hutchinson, J. W.; Tierney, G. M.; Parsons, S. L.; Davis, T. R. C. Dupuytren's Disease and Frozen Shoulder Induced by Treatment with a Matrix Metalloproteinase Inhibitor. Journal of Bone and Joint Surgery - Series B 1998, 80, 907-908.
10. Lovejoy, B.; Cleasby, A.; Hassell, A. M.; Longley, K.; Luther, M. A.; Weigl, D.; McGeehan, G.; McElroy, A. B.; Drewry, D.; Lanbert, M. H.; Jordan, S. R. Structure of the Catalytic Domain of Fibroblast Collagenase Complexed with an Inhibitor. Science 1994, 263, 375-377,
11. Gooley, P. R.; O'Connell, J. F.; Marcy, A. I.; Cuca, G. C.; Salowe, S. P.; Bush, B. L.; Hermes, J. D.; Esser, C. K.; Hagmann, W. K.; Springer, J. P.; Johnson, B. A. The NMR Structure of the Inhibited Catalytic Domain of Human Stromelysin-1. Struct. Biol. 1994, 1, 111-118.
12. Sheppard, G. S.; Florjancic, A. S.; Giesler, J. R.; Xu, L.; Guo, Y.; Davidsen, S. K.; Marcotte, P. A.; Elmore, I.; Albert, D. H.; Magoc, T. J.; Bouska, J. J.; Goodfellow, C. L.; Morgan, D. W.; Summers, J. B. Aryl Ketones as Novel Replacements for the C-Terminal Amide Bond of Succinyl Hydroxamate MMP Inhibitors. Bioorg. Med. Chem. Lett. 1998, 8, 3251-3256.
13. Sheppard, G. S.; Pireh, D.; Carrera, G. M., Jr.; Bures, M. G.; Heyman, H. R.; Steinman, D. H.; Davidsen, S. K.; Phillips, J. G.; Guinn, D. E.; May, P. D.; Conway, R. G.; Rhein, D. A.; Calhoun, W. C.; Albert, D. H.; Magoc, T. J.; Carter, G. W.; Summers, J. B., Jr. 3-(2-(3-Pyridinyl)thiazolidin-4-oyl)indoles, a Novel Series of Platelet Activating Factor Antagonists. J. Med. Chem. 1994, 37, 2011-2032.
14. Xue, C.-B.; He, X.; Roderick, J.; DeGrado, W. F.; Cherney, R. J.; Hardman, K. D.; Nelson, D. J.; Copeland, R. A.; Jaffee, B. D.; Decicco, C. P. Design and Synthesis of Cyclic Inhibitors of Matrix Metalloproteinases and TNF-α Production. J. Med. Chem. 1998, 41, 1745-1748.
15. Shuker, S. B.; Hajduk, P. J.; Meadow, R. P.; Fesik, S. W. Discovering High-Affinity Ligands for Proteins: SAR by NMR. Science 1996, 274, 1531-1534.
16. Hajduk, P. J.; Sheppard, G.; Nettesheim, D. G.; Olejniczak, E. T.; Shuker, S. B.; Meadow, R. P.; Steinman, D. H.; Carrera, G. M., Jr.; Marcotte, P. A.; Severin, J.; Walter, K.; Smith, H.; Gubbins, E.; Simmer, R.; Holzman, T. F.; Morgan, D. W.; Davidsen, S. K.; Summers, J. B.; Fesik, S. W. Discovery of Potent Nonpeptide Inhibitors of Stromelysin Using SAR by NMR. J. Am. Chem. Soc. 1997, 119, 5818-5827.
17. Michaelides, M. R.; Dellaria, J. F.; Gong, J.; Holms, J. H.; Bouska, J. J.; Stacey, J.; Wada, C. W.; Heyman, H. R.; Curtin, M. L.; Guo, Y.; Goodfellow, C. L.; Elmore, I. B.; Albert, D. H.; Magoc, T. J.; Marcotte, P. A.; Morgan, D. W.; Davidsen, S. K. Biaryl Ether Retrohydroxamates as Potent, Long-lived, Orally Bioavailable MMP Inhibitors. Bioorg. Med. Chem. Lett. 2001, 11, 1553-1556.
18. Curtin, M. L.; Florjancic, A. S.; Heyman, H. R.; Michaelides, M. R.; Garland, R. B.; Holms, J. H.; Steinman, D. H.; Dellaria, J. F.; Gong, J.; Wada, C. K.; Guo, Y.; Elmore, I. B.; Tapang, P.; Albert, D. H.; Magoc, T. J.; Marcotte. P. A.; Bouska, J. J.; Goodfellow, C. L.; Bauch, J. L; Marsh, K. C.; Morgan, D. W.; Davidsen, S, K. Discovery and Characterization of the Potent, Selective and Orally Bioavailable MMP Inhibitor ABT-770. Bioorg. Med. Chem. Lett. 2001, 11, 1557-1560.
19. Gum, R. J.; Hickman, D.; Fagerland, J. A.; Heindel, M. A.; Gagne, G. D.; Schmidt, J. M.; Michaelides, M. R.; Davidsen, S. K.; Ulrich, R. G. Analysis of Two Matrix Metalloproteinase Inhibitors and Their Metabolites for Induction of Phospholipidosis in Rat and Human Hepatocytes. Biochem. Pharm. 2001, 62, 1661-1673.
20. Itoh, T.; Tanioka, M.; Matsuda, H.; Nishimoto, H.; Yoshioka, T.; Suzuki, R.; Uehira, M. Experimental Metastasis is Suppressed in MMP-9-deficient Mice. Clinical and Experimental Metastasis 1999, 17(2), 177-181.
21. Itoh, T.; Tanioka, M.; Yoshida, H.; Yoshioka, T.; Nishimoto, H.; Itohara, S. Reduced Angiogenesis and Tumor Progression in Gelatinase A-deficient Mice. Cancer Research 1998, 58(5), 1048-1051.
22. Wada, C. K.; Holms, J. H.; Curtin, M. L.; Dai, Y.; Florjancic, A. S.; Garland, R. B.; Guo, Y.; Heyman, H. R.; Stacey, J. R.; Steinman, D. H.; Albert, D. H.; Bouska, J. J.; Elmore, I. N.; Goodfellow, C. L.; Marcotte, P. A.; Tapang, P.; Morgan, D. W.; Michaelides, M. R.; Davidsen, S. K. Phenoxyphenyl Sulfone N-Formylhydroxylamines (Retrohydroxamates) as Potent, Selective, Orally Bioavailable Matrix Metalloproteinase Inhibitors. J. Med. Chem. 2002, 45, 219-232.
23. Chang, S.-J.; Fernando, D.; Fickes, M.; Gupta, A. K.; Hill, D. R.; McDermott, T.; Parekh, S.; Tian, Z.; Wittenberger, S. J. The Development of a Large-Scale Synthesis of Matrix Metalloproteinase Inhibitor, ABT-518. Org. Process Res. Dev. 2002, 6, 329-335.
24. Crul, M.; Beerepoot, L. V.; Stokvis, E.; Vermaat, J. S. P.; Rosing, H.; Beijnen, J. H.; Voest, E. E.; Schellens, J. H. M. Clinical pharmacokinetics, pharmacodynamics and metabolism of the novel matrix metalloproteinase inhibitor ABT-518. Cancer Chemother. Pharmacol. 2002, 50, 473-478.